首页> 外文OA文献 >Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

【2h】

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

机译：第2阶段多中心试验研究聚（aDp-核糖）聚合酶抑制剂rucaparib在晚期卵巢癌和乳腺癌生殖系BRCa突变携带者中的间歇和连续给药方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Drew, Yvette; Ledermann, J; Hall, G; Rea, D; Glasspool, R; Highley, M; Jayson, Gordon; Sludden, J; Murray, J; Jamieson, D; Halford, S; Acton, G; Blackholer, Z; Mangano, R; Boddy, A; Curtin, N; Plummer, R;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer [J] . Yvette Drew, Jonathan Ledermann, Geoff Hall, British Journal of Cancer . 2016,第12期

机译：2期多中心试验研究在晚期卵巢癌和乳腺癌的种系BRCA突变携带者中聚（ADP-核糖）聚合酶抑制剂rucaparib的间歇和连续给药方案
2. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer [J] . Yvette Drew, Jonathan Ledermann, Geoff Hall, British Journal of Cancer . 2016,第7期

机译：2期多中心试验研究在晚期卵巢癌和乳腺癌的种系BRCA突变携带者中聚（ADP-核糖）聚合酶抑制剂rucaparib的间歇和连续给药方案
3. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial [J] . SandhuS.K., SchelmanW.R., WildingG., The lancet oncology . 2013,第9期

机译：BRCA突变携带者和散发性癌症患者中的聚（ADP-核糖）聚合酶抑制剂尼拉帕利（MK4827）：1期剂量递增试验
4. Molecular determinants of sensitivity to poly(ADP-ribose) polymerase inhibitors in epithelial ovarian cancer. [D] . O'Connor, Kevin. 2016

机译：分子决定因素对上皮性卵巢癌中聚（ADP-核糖）聚合酶抑制剂的敏感性。
5. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer [O] . Yvette Drew, Jonathan Ledermann, Geoff Hall, 2016

机译：2期多中心试验研究在晚期卵巢癌和乳腺癌的生殖系BRCA突变携带者中聚（ADP-核糖）聚合酶抑制剂rucaparib的间歇和连续给药方案
6. The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients [O] . Szabolcs Molnár, Beáta Vida, Lívia Beke, 2021

机译：野生型和BRCA-突变患者卵巢癌组织中聚（ADP-核糖）聚合酶表达的预后相关性
7. Treatment of BRCA1/2 Hereditary BRCA1/2 and Sporadic Breast Cancer with Poly(ADP-Ribose) Polymerase Inhibitors and Chemotherapy [R] . DeSoto, J. A. 2009

机译：聚（aDp-核糖）聚合酶抑制剂和化疗治疗BRCa1 / 2遗传性BRCa1 / 2和散发性乳腺癌

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

著录项

相似文献

相关主题

期刊订阅